Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
U.S. Stock Market Leverage Risk Rises, Margin Debt Reaches Historic High of 4.5% of GDP

U.S. Stock Market Leverage Risk Rises, Margin Debt Reaches Historic High of 4.5% of GDP

CointimeCointime2026/07/19 22:24

Data from the NYSE and FINRA reveal that the scale of margin debt in the U.S. has surged to approximately 4.5% of the Gross Domestic Product (GDP), setting a historical record and surpassing previous peaks during the 2000 dot-com bubble, the 2008 financial crisis, and the market highs of 2021. Margin debt refers to the liabilities incurred by investors when borrowing money to purchase stocks. High leverage can amplify investment returns in a bull market, but it significantly increases the risk of forced selling during downturns. Although this indicator cannot precisely predict market turning points, it reflects that the current level of investor leverage is at an unprecedented high relative to the size of the economy in modern history.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

A $5.7 billion patent verdict has been issued, Burford Capital (BUR.US) may receive $1.4 billion, and its share price soared by more than 12%.

Burford Capital Ltd. surged more than 12% on Monday, marking its largest intraday increase since the end of March, after a federal jury delivered a verdict in a patent case involving Apple.

智通财经•2026/09/29 03:11

Pfizer (PFE.US), BioNTech (BNTX.US), and Moderna (MRNA.US) seek dismissal of Bayer’s Monsanto mRNA patent lawsuit, but the judge rejects the request

A federal judge in Delaware on Monday rejected the requests from Pfizer, BioNTech, and Moderna to dismiss a lawsuit filed against them by Monsanto, a subsidiary of the German pharmaceutical giant Bayer. The lawsuit concerns these pharmaceutical companies' use of a patent related to mRNA technology.

智通财经•2026/09/29 02:46